You’re on our free ad-supported tier. Upgrade to NewsNow Essentials now and get your favourite news platform, faster, slicker and ads free.You’re on our free tier. Upgrade to NewsNow Essentials now. Faster, slicker and ads free.You’re on our free tier. Upgrade and go ads free now!

Home
Hot Topics
US
Politics
World
Sports
Business
Crypto
Entertainment
Lifestyle
Tech
Science

Celltrion
Biotech
Moderna
Topics

Advertisement

Celltrion

Share

Top Latest Popular

Celltrion files for European approval of Cosentyx biosimilar CT-P55, accelerating push into key global markets Korea Biomedical Review 2d

Korea Biomedical Review 2d

European Medicines Agency

Celltrion draws bullish broker outlooks after second straight sales beat Korea Biomedical Review 02:27 Wed, 08 Jul

Korea Biomedical Review 02:27 Wed, 08 Jul

Celltrion and teva’s TRUXIMA® becomes first interchangeable rituximab biosimilar in U.S. JD Supra 17:14 Fri, 10 Jul

JD Supra 17:14 Fri, 10 Jul

Advertisement

Advertisement

Celltrion wins Korea phase 1 approval for Tremfya biosimilar Korea Biomedical Review 07:47 Wed, 15 Jul

Korea Biomedical Review 07:47 Wed, 15 Jul

Celltrion gets green light for Phase 1 clinical trial of 'Tremfya' biosimilar in South Korea Asia Today 02:00 Wed, 15 Jul

Asia Today 02:00 Wed, 15 Jul

Korean Politics Pharma

Celltrion’s TRUXIMA® approved as first interchangeable RITUXAN® biosimilar JD Supra 20:18 Tue, 14 Jul

JD Supra 20:18 Tue, 14 Jul

Advertisement

Advertisement

Latest

Friday

Celltrion files for European approval of Cosentyx biosimilar CT-P55, accelerating push into key global markets Korea Biomedical Review 06:57 Fri, 24 Jul

In the last month

Celltrion wins Korea phase 1 approval for Tremfya biosimilar Korea Biomedical Review 07:47 Wed, 15 Jul

Celltrion gets green light for Phase 1 clinical trial of 'Tremfya' biosimilar in South Korea Asia Today 02:00 Wed, 15 Jul

Celltrion’s Truxima® Approved as First Interchangeable Rituxan® Biosimilar JD Supra 20:18 Tue, 14 Jul

Celltrion licenses autoimmune disease antibody technology from Catholic University Korea Biomedical Review 02:37 Tue, 14 Jul

Celltrion and Teva’s TRUXIMA® Becomes First Interchangeable Rituximab Biosimilar in U.S. JD Supra 17:14 Fri, 10 Jul

Celltrion’s high-margin biosimilars gain ground across Europe, strengthening H2 growth outlook Korea Biomedical Review 02:49 Fri, 10 Jul

Spotlight On: Biosimilar Litigations - July 2026 JD Supra 21:41 Thu, 09 Jul

Spotlight On: Rituxan® (rituximab) / Truxima® (rituximab-abbs) / Ruxience® (rituximab-pvvr) / Riabni™ (rituximab-arrx) - July 2026 JD Supra 17:46 Thu, 09 Jul

Celltrion draws bullish broker outlooks after second straight sales beat Korea Biomedical Review 02:27 Wed, 08 Jul

Advertisement

Advertisement

Advertisement

About our Celltrion news

Latest news on Celltrion, a biopharmaceutical company headquartered in Incheon, South Korea.

News Now

Our Sites

News Now Nigeria

News Now România

News Now Italia

News Now Canada

News Now Australia

Work with us

Publisher Network

Dockside Online IDE

Legal

Subscription Terms

© Copyright 1997 - 2026 NewsNow Publishing Limited. All rights reserved.

Biotech Biotech
Back to Business Biotech
- GM Food GM Food
- AbbVie AbbVie
- Amgen Amgen
- Biogen Biogen
- BioNTech BioNTech
- Celltrion Celltrion
- Genentech Genentech
- Gilead Sciences
- Illumina Illumina
- Moderna Moderna